Clinigen’s FY15 trading update highlights solid fundamentals, with all divisions delivering organic revenue and profit growth. The results are ahead of our forecasts, with revenues of at least £183.6m (versus our £178.0m) and underlying EBITDA of £32.2m (£31.9m). The Idis businesses, acquired in April, are being integrated well and contributing attractive organic growth rates. Cash generation has remained strong, net debt is £78.0m (our forecast was £
23 Jul 2015
Strong performances across all four divisions
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong performances across all four divisions
- Published:
23 Jul 2015 - Author:
- Pages:
Clinigen’s FY15 trading update highlights solid fundamentals, with all divisions delivering organic revenue and profit growth. The results are ahead of our forecasts, with revenues of at least £183.6m (versus our £178.0m) and underlying EBITDA of £32.2m (£31.9m). The Idis businesses, acquired in April, are being integrated well and contributing attractive organic growth rates. Cash generation has remained strong, net debt is £78.0m (our forecast was £